|
|
|
|
Vol. 61, Issue 2, 320-325, February 2002
Departments of Chemistry & Biochemistry and Pharmacology, Cancer Center, University of California, San Diego, La Jolla, California (A.S., C.P.S., R.H.T.) and Department of Gastroenterology and Hepatology, Medizinische Hochschule Hannover, Hannover, Germany (M.P.M.)
| |
Abstract |
|---|
|
|
|---|
NAD(P)H:quinone oxidoreductase (NQO1) and dihydronicotinamide
riboside:quinone oxidoreductases (NQO2) are cytosolic flavoproteins that catalyze the two-electron reduction of quinones and quinoid compounds to hydroquinones, thereby promoting detoxification and preventing the formation of highly reactive oxygen species, which lead
to DNA and cell damage. Two NQO isoforms, designated NQO1 and NQO2,
have been cloned and sequenced. To elucidate their role in
carcinogenesis, the gene expression of human NQO1 and NQO2 in paired
normal and tumor tissue samples was examined. Quantitative triplex
reverse transcriptase polymerase chain reaction was employed to
analyze NQO1 and NQO2 mRNA expression in normal hepatic and biliary
tissue as well as in cholangiocellular carcinomas (CCC), hepatocellular
carcinomas (HCC), and focal nodular hyperplasias (FNH). Coexpression of
-actin RNA was used as an internal reference standard and linear
ranges of transcript amplification were established for each sample. In
normal hepatocellular tissue, the two NQO isoforms were differentially
regulated, with a higher expression of NQO2 than NQO1. Malignant
hepatocellular tissue (HCC), however, displayed up-regulation of NQO1
and down-regulation of NQO2. Regulation of either transcript was not
seen in benign hepatocellular tumor tissue (FNH), which indicates a
reciprocal control of NQO genes in hepatocarcinogenesis. Normal biliary
tissue expressed a significantly higher level of NQO1 transcripts
compared with normal liver, whereas biliary NQO2 levels were
significantly lower than in hepatocellular tissue. Comparing the levels
of expression in normal and malignant biliary tissue (CCC), no
significant differences were noted between the expression levels of
either transcript. Thus, this study provides evidence for differential
hepatic and biliary regulation of both NQO1 and NQO2.
| |
Introduction |
|---|
|
|
|---|
Quinones
are a class of compounds ubiquitous in nature; they are natural
byproducts of plants and vegetables. Humans are exposed to these agents
either through dietary intake of naturally occurring quinones or
through inhalation of airborne environmental contaminants generated
through various combustion processes, such as automobile exhaust and
cigarette smoke. Quinones undergo metabolism by either a one- or
two-electron reduction. One-electron reduction is carried out by the
cellular reductases, such as xanthine oxidoreductase, ubiquinone
oxidoreductase, cytochrome P450 reductase, and cytochrome b5 reductase.
This process generates semiquinone radicals, which can undergo redox
cycling in the presence of molecular oxygen leading to the formation of
reactive oxygen species (e.g., superoxide anion, perhydroxyl radical,
hydrogen peroxide, hydroxyl radical). Reactive oxygen species promote
oxidative damage. In contrast, two-electron reduction is catalyzed by
the NAD(P)H/dihydronicotinamide riboside (NRH):quinone oxidoreductases
(NQOs), producing hydroquinones. These metabolites are more stable and
can also be targeted for additional metabolism through conjugation with
glutathione or glucuronic acid. In promoting obligatory two-electron
reduction, quinone oxidoreductases prevent the formation of reactive
semiquinone intermediates. Thus, they play an important role in
cellular detoxification (Lind et al., 1982
; Thor et al., 1982
; Joseph
and Jaiswal, 1994
) and, by preventing the generation of reactive oxygen
species, are considered part of the human antioxidant defense system.
Quinone oxidoreductases were originally felt to use NADH and NADPH as
electron donors (Ernster and Navazio, 1958
) in the reduction of
quinones to hydroquinones (Iyanagi and Yamazaki, 1970
). It is now known
that NAD(P)H:quinone oxidoreductase 1 (NQO1) uses NAD(P)H, whereas
NRH:quinone oxidoreductase 2 (NQO2) uses the nonbiogenic cosubstrate
NRH as the electron donor (Wu et al., 1997
). Recombinant studies have
concluded that human NQO1 and NQO2 possess approximately 49% amino
acid sequence identity. Although the genes for NQO1 and
NQO2 are on different chromosomes, there are regions of
considerable nucleotide conservation, indicating that the two genes are
evolutionarily conserved. However, because there is considerable amino
acid divergence between the proteins and the requirements for electron
donation are served by different cosubstrates, expression experiments
have demonstrated that NQO1 and NQO2 exhibit remarkable differences in
substrate specificity. Although it is believed that the formation of
hydroquinones leads to detoxification, two-electron reduction catalyzed
by both NQO1 and NQO2 can also activate certain substrates, such as
quinone-containing antitumor drugs. The end result of such metabolism
is the formation of highly reactive alkylating species, which readily
associate with cellular macromolecules to initiate a cytotoxic reaction.
Because quinone oxidoreductases have been speculated to serve a role in
genoprotection, studies in both humans and rodents have been undertaken
to examine the relationship between these proteins and the incidence of
certain diseases. In one study, NQO1 activity was estimated to be
absent in 4% of the population (Edwards et al., 1980
). This could be
attributed to a C-to-T missense mutation at codon 187 (Pro to Ser),
where the allele carrying the P187S change has been found to be
inactive in cells that are homozygous (T/T) for the mutation (Traver et
al., 1992
, 1997
). Linkage studies examining the P187S null allele in
humans with cancers of the lung, kidney, prostate and gastrointestinal
tract have been investigated and the results linking this mutation to disease have been inconclusive. Although several studies show no
correlation, others have indicated that the P187S allele may be
positively linked (Chen et al., 1999
; Larson et al., 1999
; Lin et al.,
1999
). Interestingly, the P187S null allele (T/T) has been associated
with benzene toxicity (Rothman et al., 1997
) in humans (Moran et al.,
1999
), which is characterized as an elevated risk of developing
benzene-induced leukemia. In addition, the metabolites of benzene that
accumulate in the bone marrow, including the hydroquinone and
benzoquinone, are also positive regulators of NQO1, leading to
transcriptional activation of the gene. It has also been shown that T/T
genotype individuals are resistant to induction and thus express little
NQO1 RNA, indicating that a regulatory polymorphism may also be
involved in eliciting individuals susceptible to benzene toxicity (Pink
et al., 2000
). Additional evidence that NQO1 participates in
detoxifying quinones comes from recent efforts to generate
NQO1-null mice. Mice lacking NQO1 (NQO1
/
) exhibit an
increased sensitivity to the toxic effects of menadione, indicating
that NQO1 supports a protective role against oxidative stress. Although
the NQO2 gene does show a restriction fragment length
polymorphism (Jaiswal et al., 1990
; Long and Jaiswal, 2000
), no studies
have been conducted linking this genotype to cancer or toxicity in humans.
Natural cellular defenses against environmental insults can be
attributed to the recruitment of appropriate detoxification systems
within the cell as well as an understanding of the tissue-specific distribution of these enzymes. NQO1 has been shown by direct
immunohistochemistry to be expressed in many normal human tissues as
well as in solid tumors from thyroid, adrenal, breast, ovarian, colon,
cornea, and non-small-cell lung cancers (Siegel et al., 1998
; Siegel
and Ross, 2000
). Comparing normal and malignant tissue for quinone reductase activities, NQO was reported to be up-regulated in malignant tissue of the colon, breast, lung and liver and down-regulated in solid
tumors of the stomach and kidney (McGinty et al., 1973
; Koudstaal et
al., 1975
; Schor and Cornelisse, 1983
; Schlager and Powis, 1990
).
Elevation of NQO1 RNA in solid tumors has also been demonstrated
(Cresteil and Jaiswal, 1991
; Belinsky and Jaiswal, 1993
), but
regulation in tumors is not a universal phenomenon. Immunohistochemical
analysis did not detect NQO1 protein in small-cell lung cancer or
carcinoid lung tumors (Siegel and Ross, 2000
), and no differences were
observed in DT-diaphorase (NQO1) activity in colon between normal and
tumor tissue (De Waziers et al., 1991
). Several studies indicate that
NQO1 levels in the gastrointestinal tract are highest in stomach and
ileum, whereas levels are low in colon and liver tissue (Schlager and
Powis, 1990
; Siegel and Ross, 2000
).
Limited studies have been undertaken to examine NQO2 expression in
human tissues. Using Northern blot analysis, NQO2 was found to be
expressed heart, brain, lung, liver, kidney, and skeletal muscle, but
no RNA was detected in placenta (Jaiswal, 1994
). No previous study has
investigated NQO2 enzyme activity or mRNA expression in malignant human tissues.
A comparative analysis of NQO1 and NQO2 would be of particular interest in metabolically active tissue. Liver tissue is differentiated into two metabolically active cell types involved in detoxification and excretion: hepatocytes and cholangiocytes. Different malignant tumors develop from these cell types, offering the unique opportunity to examine the regulation of NQO1 and NQO2 in normal and malignant tissues of related function and origin. In this study, we developed a triplex reverse transcriptase PCR method and employed Southern and Northern blot analyses to investigate the expression of both NQO1 and NQO2 mRNA in normal and malignant hepatocellular and cholangiocellular tissue as well as in benign hepatocellular tumors.
| |
Materials and Methods |
|---|
|
|
|---|
Tissue Procurement.
Paired tissue samples of normal and
tumor tissue were obtained from 19 patients undergoing hemihepatectomy
or liver transplantation (University of Hannover Medical Center in
Hannover, Germany) for HCC [n = 12 patients, age
58 ± 10.4 years (mean ± S.D.), 11 men, 1 woman], FNH
(n = 3 patients, mean age 37.3 ± 14.5 years, all women), and CCC (n = 4 patients, mean age 56.8 ± 18.5 years, three men, one woman). Only tissue without any visible sign
of necrosis was collected. Diagnosis was established through
histological examination. In every case, the sample pair of normal and
tumor tissue was taken from the same resection specimen, immediately snap-frozen in liquid nitrogen, and continuously stored at
80°C until analysis.
Isolation of RNA.
The isolation of RNA was based on the
protocol of Chomczynski and Sacchi (1987)
and has been described in
detail previously (Strassburg et al., 1997b
). Approximately 200 mg of
frozen tissue sample were pulverized in liquid nitrogen in a mortar.
The frozen tissue powder was immediately lysed in 1 ml of acidic
phenol/guanidine thiocyanate solution (TriPure; Roche Molecular
Biochemicals, Mannheim, Germany). Samples were not allowed to
thaw at any point of the procedure. RNA was extracted by addition of
chloroform, resuspended in 50 µl of diethylpyrocarbonate-treated
water and frozen at
80°C until analysis. Quantity and purity of the
RNA were determined by spectrophotometry at A260
nm and A280 nm. Possible DNA
contamination was monitored by employing PCR-primer pairs for
amplification of
-actin, NQO1 and NQO2 cDNA that span several
exon/intron junctions leading to amplification products of different
sizes if generated from genomic or cDNA templates.
Reverse Transcription of RNA. Three micrograms (in 5 µl of water treated with diethyl pyrocarbonate) of RNA were denatured at 70°C for 10 min in the presence of 1 µl of oligo(dT)12-18 (0.5 µg/µl) followed by chilling on ice for 2 min. In a volume of 19 µl containing 20 mM Tris-HCl, pH 8.4, 50 mM KCl, 2.5 mM MgCl2, 10 mM dithiothreitol, and 0.5 mM each dNTP, the RNA was incubated at 42°C for 5 min before the addition of 1 µl of reverse transcriptase (200 units/µl SuperScript II RT; Invitrogen, Carlsbad, CA). The final volume of 20 µl was incubated at 42°C for 50 min followed by 70°C for 15 min. The incubations were then chilled on ice before use in PCR.
Triplex RT-PCR Amplification of NQO1, NQO2 and
-Actin
Transcripts.
Six primers were generated for the amplification of
human NQO1, NQO2 and
-actin by automated phosphoramidite chemistry
at the UCSD Cancer Center Molecular Biology Core facility. PCGene and
GenBank Blastn software were employed to exclude cross-reactivity and
self-complementarity of primers. Primer melting temperatures ranged from 54-63°C. All of the following accession and
base-pair numbers refer to sequences deposited in GenBank:
-actin
sense primer (accession number M10278, bases 942-962),
5'-ggcggcaccaccatgtaccct-3';
-actin antisense primer (accession
number M10278, bases 1123-1143), 5'-aggggccggactcgtcatact-3'; NQO1
sense primer (accession number J03934, bases 92-113),
5'-gaggacctccttcaactatgcc-3'; NQO1 antisense primer (accession number
J03934, bases 437-457), 5'-cctttgtcatacatggcagcg-3'; NQO2 sense primer
(accession number J02888, bases 214-234), 5'-ggaacccaagtctttcaacgg-3';
NQO2 antisense primer (accession number J02888, bases 816-836),
5'-tgggctcttccttccagatgg-3'. Primers for
-actin have been published
previously (Strassburg et al., 1997b
).
-actin were coamplified in a volume of 96 µl
containing 1.5 mM MgCl2, 20 mM Tris-HCl, pH 8.4, 50 mM KCl, 1.0% Triton X-100, 0.2 mM concentration of each dNTP, 1.0 µM concentration of each primer, 4 units of VENT DNA polymerase (New
England Biolabs, Beverly, MA) and 0.625, 1.25, 2.5, or 5 µl of cDNA
solution. The mixture was incubated at 94°C for 3 min followed by 30 cycles of 94°C (30 s), 57°C (30 s), and 72°C (30 s) and a final
7-min incubation at 72°C.
-Actin primers were added to a
concentration of 0.2 µM each after the first six cycles for a final
reaction volume of 100 µl. Triplex RT-PCR reactions for each sample
were performed in duplicate in a PerkinElmer GeneAmp PCR System 2400. PCR products were stored at
20°C. Linear kinetics for all three coamplified products were documented by amplification using different dilutions of cDNA template in all studied samples and by terminating PCR amplification reactions after 26, 28, 30, 32, and 34 cycles. Independence of triplex coamplification product generation was documented by comparison with single or duplex PCR amplification of the
same amplicons.
Quantitation of PCR Products.
Fifteen microliters of each
PCR reaction was resolved in a 2% agarose gel containing 1 µg/ml
ethidium bromide. Gels were photographed using Polaroid (Cambridge, MA)
type 665 positive/negative film and negatives were used to quantify
bands by laser densitometry (LKB 2222-020 UltoScan XL densitometer;
LKB, Bromma, Sweden). The results for human
-actin were used as
internal standard for each sample. Arbitrary units were calculated
relative to
-actin.
Cloning and Analysis of the 366-bp NQO1 Transcript and the 623-bp
NQO2 Transcript.
After synthesis of cDNA from total RNA, the 366- and 623-bp transcripts were PCR-amplified separately. The NQO1 sense
primer (5'-gaggacctccttcaactatgcc-3') and the NQO2 sense primer
(5'-ggaacccaagtctttcaacgg-3') were designed to incorporate a
HindIII restriction endonuclease cleavage site 5' to the
respective 366- or 623-bp transcript. The NQO2 antisense primer
(5'-tgggctcttccttccagatgg-3') contained an XbaI site 3' to
the NQO2 transcript. The NQO1 antisense primer (5'-cctttgtcatacatggcagcg-3') was not altered. The amplified NQO1 and
NQO2 PCR products were column-purified with the QIAquick PCR Purification Kit (QIAGEN, Hilden, Germany). The NQO1 PCR product was
digested with HindIII and cloned into the
HindIII/SmaI sites of the pBluescript
KS+ vector (Stratagene, La Jolla, CA), whereas
the NQO2 PCR product was digested with
HindIII/XbaI and cloned into the
HindIII/XbaI sites of the pBluescript
KS+ vector. Ligation products were transformed
into Escherichia coli MN522 cells, positive clones selected
and sequences were determined by dideoxy sequence analysis (Sanger et
al., 1977
).
Southern Blot Analysis.
Triplex RT-PCR products were
separated in a 1% agarose gel. The DNA was transferred to a
nitrocellulose membrane (Immobilon-NC; Millipore, Bedford, MA) after
incubating the gel for 20 min in a buffer containing 1.5 M NaCl and 0.5 N NaOH followed by neutralization for 45 min in a buffer containing 1.5 M NaCl and 1 M Tris-HCl, pH 7.4. Hybridization was performed with the
nick-translated 32P-labeled (Amersham
Biosciences, Piscataway, NJ) NQO1 transcript. Approximately
108 cpm/ml was used in hybridization. Membranes
were washed with 2× standard saline citrate/0.1% SDS at room
temperature and 0.1× standard saline citrate/0.1% SDS at 42°C (1×
standard saline citrate = 15 mM sodium citrate, pH 7.0, containing
150 mM NaCl). Dried membranes were exposed to X-ray film then stripped
by two washes with boiling 0.1% SDS solution of 15 min each,
rehybridized with the 32P-labeled NQO2
transcript, and again exposed to X-ray film. After stripping for a
second time, rehybridization with a 32P-labeled
full-length human
-actin probe was followed by a third exposure to
X-ray film.
Northern Blot Analysis.
Twenty micrograms of total RNA were
separated in a 1% denaturing agarose gel containing 7% formaldehyde
and transferred to a nitrocellulose membrane. Hybridization was
performed with the nick-translated, 32P-labeled
NQO1 transcript overnight. Dried membranes were exposed to X-ray film
at
80°C. For rehybridization, the membranes were then stripped by
washing with boiling 0.1% SDS solution, rehybridized with the
32P-labeled NQO2 transcript, and exposed to X-ray
film. Once again, stripping was carried out, followed by
rehybridization with a 32P-labeled full-length
human
-actin probe.
| |
Results |
|---|
|
|
|---|
Expression of the NQO1 and
NQO2 Genes in Normal and Tumorigenic Tissue.
To
examine the expression of NQO1, NQO2, and
-actin genes in human tumor and normal tissue, a triplex RT-PCR
amplification protocol was developed so that levels of gene expression
were quantitated during the linear amplification phase of each
transcript. PCR primers were selected yielding amplification products
of the following sizes: 202 bp (
-actin), 366 bp (NQO1), and 623 bp
(NQO2). Each primer pair was designed to anneal specifically to
different exons.
-actin transcripts were analyzed in 12 HCC, 3 FNH,
and 4 CCC tissue samples and paired with expression patterns from
corresponding normal tissue that was taken adjacent to each tumor.
Analysis of PCR products from normal liver and biliary tissue (Fig.
1) demonstrated NQO2 to be
expressed in both, with the relative abundance of NQO2 being slightly
lower in biliary epithelium (p < 0.001). However,
laser densitometry quantification and calculation of band intensities
relative to
-actin documented significantly greater expression of
NQO1 (p = 0.007) in normal biliary tissue
than in hepatocellular tissue. This is somewhat in contrast to analysis
of bile duct epithelium by immunohistochemistry, where only trace
amounts of NQO1 were detected (Siegel and Ross, 2000
|
|
|
-actin from samples of the benign liver tumor FNH did
not demonstrate appreciable regulation of NQO transcripts (Fig.
4, right). Furthermore, differential
regulation of the NQO1 and NQO2 RNA transcripts was not found between
normal biliary tissue and the malignant CCC (Fig. 4, left).
|
|
| |
Discussion |
|---|
|
|
|---|
Metabolism by quinone oxidoreductases is considered to bypass the
generation of reactive oxygen species from quinone derivatives through
a unique two-electron reduction that facilitates the detoxification and
elimination of xenobiotic and carcinogenic compounds (Lind et al.,
1982
; Thor et al., 1982
; Prestera et al., 1993
; Joseph and Jaiswal,
1994
). This process therefore plays an important role among the
cellular metabolic defense mechanisms. On the other hand, NQOs have
been implicated in the metabolic activation of chemotherapeutic agents
(Riley and Workman, 1992
). To initiate experiments studying their role
in cancer development, data on specific NQO tissue expression was examined.
For further definition of the potential role that NQOs assume in the metabolism of xenobiotic compounds, expression studies in tissue types distinguished by a high degree of metabolic activity are of particular interest. Liver tissue exhibits this property; furthermore, it is differentiated into two major specialized cell types: hepatocytes and cholangiocytes. These characteristics provide the means for a tissue-specific and, with both benign and malignant tumors arising from the same cellular origin, tumor-specific analysis of NQO1 and NQO2 expression in metabolically active tissue. We demonstrate the parallel investigation of NQO1 and NQO2 gene expression in hepatocellular and cholangiocellular tissue by means of a quantitative one-step triplex RT-PCR method that permits the specific identification and amplification of the two NQO transcripts.
Analysis of NQO1 expression in liver tissue demonstrated low NQO1
transcript levels in normal hepatocellular tissue and a statistically
significant up-regulation in malignant HCC, confirming previous
observations on the expression of NQO1 in liver tumors (Cresteil and
Jaiswal, 1991
; Belinsky and Jaiswal, 1993
). In comparison, the
predominant quinone oxidoreductase in liver is NQO2. Expression of NQO2
was observed to be slightly higher in normal hepatocellular tissue
compared with malignant hepatocellular tumor tissue (Figs. 2, 3, and
5). While NQO1 is dramatically regulated in hepatocellular carcinoma,
no statistically significant regulation of either transcript was
observed between normal hepatocellular tissue and FNH, a benign hepatocellular tumor (Figs. 4 and 5). It remains unclear whether the
regulatory changes in HCC are early events in carcinogenesis or
consequences of cancer development, but these results demonstrate that
the process of carcinogenesis affects primarily NQO1.
Compared with the regulation observed for NQO1 in HCC and not in FNH,
the UDP-glucuronosyltransferase 1A (UGT1A) locus
has previously been demonstrated to be down-regulated in HCC in
contrast to no regulation in FNH tumor tissue (Strassburg et al.,
1997a
). In addition, regulation in premalignant liver adenoma tissue
was observed, suggesting that UGT1A regulation is an early event in hepatocarcinogenesis. Interestingly, UGT1A down-regulation was not only
seen in malignant liver tumors of hepatocellular origin but also in
those of cholangiocellular origin. Quinone oxidoreductases, however,
display a regulatory difference between hepatocellular and
cholangiocellular tissue. Whereas NQO1 and NQO2 expression was
demonstrated to be regulated in HCC, a more individual regulatory pattern was observed in CCC leading to no statistically significant regulatory results (Fig. 5). This regulatory
difference between liver and biliary tissue was even more striking when
normal tissue samples were compared. The NQO1 transcript was distinctly
more abundant in cholangiocellular than in hepatocellular tissue (Fig. 1), whereas expression of the NQO2 transcript is
abundant in both hepatocellular and cholangiocellular tissue. These
data correlate with a report by Martin et al. who observed a
higher tissue activity of DT-diaphorase (NQO1) in a gallbladder tissue
sample than in normal liver tissue.
Because of elevations in NQO1 activity in solid tumors relative to
surrounding normal tissue, this activity has been exploited for
catalyzing the two electron reduction of antitumor agents with the
hopes of being effective cytotoxic agents (Ross et al., 2000
). Indeed,
experiments using cell lines that overexpress NQO1 have demonstrated a
linkage to the cytotoxic actions of NQO1 antitumor substrates (Kelland
et al., 1999
; Pink et al., 2000
; Okamura et al., 2000
), although
certain cells with elevated levels of NQO1 seem to be resistant to
NQO1-mediated cytotoxicity (Brunton et al., 1998
). It is also important
to note that although NQO1 gene expression may be elevated
in liver tumors, other factors, such as the inheritance of the NQO1
P187S (T/T) allele, render the protein inactive (Traver et al., 1997
;
Siegel et al., 1999
), thus making it unlikely that the antitumor
compounds will be effectively metabolized to cytotoxic agents. Our
studies indicate that not all malignant tumors, such as CCC, would be
an appropriate target for NQO1-mediated bioactivation of antitumor
agents, because there is little difference in NQO1 expression between
normal and malignant tissue. In addition, identifying novel
cosubstrates for the activation of potential antitumor substrates by
NQO2 may also be a challenge because NQO2 does not seem to be
significantly regulated between normal and malignant tissues.
| |
Footnotes |
|---|
Received July 17, 2001; Accepted October 31, 2001
This work was supported by United States Public Health Service grant GM36590.
Robert H. Tukey, Ph.D., Department of Pharmacology, UCSD Cancer Center, BSB 4th Floor, Rm. 4021, 9500 Gilman Dr., La Jolla, CA 92093-0636. E-mail: rtukey{at}ucsd.edu
| |
Abbreviations |
|---|
NRH, dihydronicotinamide riboside; NQO1, NAD(P)H:quinone oxidoreductase 1; NQO2, dihydronicotinamide riboside:quinone oxidoreductase 2; PCR, polymerase chain reaction; HCC, hepatocellular carcinoma; FNH, focal nodular hyperplasia; CCC, cholangiocellular carcinoma; RT, reverse transcriptase; bp, base pair(s); kb, kilobases.
| |
References |
|---|
|
|
|---|
T polymorphism with a decreased lung cancer risk.
Cancer Res
59:
3045-3048
T polymorphism in the NAD(P)H:quinone oxidoreductase (NQO1) gene in patients with primary and therapy-related myeloid leukemia.
Blood
94:
803-807
T mutation and rapid fractional excretion of chlorzoxazone.
Cancer Res
57:
2839-2842This article has been cited by other articles:
![]() |
K.-D. Yu, G.-H. Di, W.-T. Yuan, L. Fan, J. Wu, Z. Hu, Z.-Z. Shen, Y. Zheng, W. Huang, and Z.-M. Shao Functional polymorphisms, altered gene expression and genetic association link NRH:quinone oxidoreductase 2 to breast cancer with wild-type p53 Hum. Mol. Genet., July 1, 2009; 18(13): 2502 - 2517. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. S. Ahn, X. Gong, G. Sethi, M. M. Chaturvedi, A. K. Jaiswal, and B. B. Aggarwal Deficiency of NRH:Quinone Oxidoreductase 2 Differentially Regulates TNF Signaling in Keratinocytes: Up-regulation of Apoptosis Correlates with Down-regulation of Cell Survival Kinases Cancer Res., October 15, 2007; 67(20): 10004 - 10011. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Siegel, D. L. Gustafson, D. L. Dehn, J. Y. Han, P. Boonchoong, L. J. Berliner, and D. Ross NAD(P)H:Quinone Oxidoreductase 1: Role as a Superoxide Scavenger Mol. Pharmacol., May 1, 2004; 65(5): 1238 - 1247. [Abstract] [Full Text] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||